<DOC>
	<DOC>NCT01335373</DOC>
	<brief_summary>Vaginitis is the most common gynecologic diagnosis in the primary care setting. In approximately 90 percent of affected women, this condition occurs secondary to bacterial vaginosis, vulvovaginal candidiasis, trichomoniasis or mixed infection. Neo-Penotran Forte is registered for treatment of these most common vaginal infections. Efficacy and safety of this product is already established, and this observational study was designed to learn more about practical use of Neo-Penotran® Forte in real life setting.</brief_summary>
	<brief_title>Observational Program Neo-Penotran® Forte</brief_title>
	<detailed_description />
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Vaginal Diseases</mesh_term>
	<mesh_term>Vaginosis, Bacterial</mesh_term>
	<mesh_term>Vaginitis</mesh_term>
	<mesh_term>Candidiasis, Vulvovaginal</mesh_term>
	<mesh_term>Trichomonas Vaginitis</mesh_term>
	<mesh_term>Metronidazole</mesh_term>
	<mesh_term>Miconazole</mesh_term>
	<criteria>Patients older than 18 years with previously taken decision of their gynecologist to prescribe NeoPenotran Forte according to registered indications, and microbiological tests were performed. Presence of contraindications according to package insert.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Vaginal candidiasis</keyword>
	<keyword>Bacterial vaginosis (also known as non-specific, or Gardnerellosis, or anaerobic vaginosis)</keyword>
	<keyword>Trichomonal vaginitis</keyword>
	<keyword>Vaginitis due to mixed infection</keyword>
</DOC>